Early Low-dose ASpirin Use After Intravenous Thrombolysis for Acute Ischemic Cerebral Infarction（ELASTIC）

NCT07563673 — Phase 4, Not yet recruiting, 210 participants, Beijing Chao Yang Hospital

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Safety and Efficacy of Treatment With Early Low-dose ASpirin Use After Intravenous Thrombolysis for Acute Ischemic Cerebral Infarction (ELASTIC): A Randomized, Open-label, Blinded Endpoint, Clinical Trial

Registry	NCT07563673, acronym ELASTIC
Status	Not yet recruiting
Phase	Phase 4
Study type	Interventional; randomized, parallel, masking: none, treatment
Enrollment	210 (Estimated)
Sponsor	Beijing Chao Yang Hospital (Other)
Conditions	Cerebral Infarction, Thrombolysis
Interventions	Aspirin (Early, 2h), Aspirin (Standard, 24h) (Drug)
Dates	start 2026-05-01 (estimated), primary completion 2027-09-30 (estimated), completion 2027-12-31 (estimated), first posted 2026-05-04, last updated 2026-05-08
Locations	1 site in China

-Summary

This study evaluates whether early administration of low-dose aspirin (100mg) at 2 hours post-intravenous thrombolysis, compared to the standard timing of 24 hours, improves functional outcomes in patients with acute ischemic stroke. Intravenous thrombolysis is effective for very early treatment of acute ischemic stroke. However, current guidelines recommend starting antiplatelet therapy 24 hours after thrombolysis to avoid symptomatic intracranial hemorrhage (SICH), a recommendation not based on prospective clinical studies. Early re-occlusion of recanalized arteries due to platelet aggregation occurs in 14-34% of cases and is associated with poor prognosis. The average incidence of SICH is 2.4%, with fatal SICH occurring in only 0.28%. Thus, the impact of re-occlusion on poor prognosis may outweigh the risk of SICH. In this prospective, randomized, open-label trial with blinded endpoint evaluation, participants are assigned to receive aspirin 100mg either at 2 hours (early group) or at 24 hours (standard group) after thrombolysis. The primary outcome is the proportion of patients with a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-2 at 3 months. Safety outcomes include the incidence of SICH and all-cause mortality at 3 months. This study will provide clinical evidence regarding the optimal timing for initiating antiplatelet therapy after thrombolysis in acute ischemic stroke.

Expand all sections · Collapse all

+Arms and interventions

Arm	Type	Interventions	Description
Early Aspirin Group	Experimental	Drug: Aspirin (Early, 2h)	Participants receive oral aspirin 100mg at 2 hours after rt-PA thrombolysis. A follow-up CT scan is performed at 2 hours post-thrombolysis. If no intracranial hemorrhage is confirmed, aspirin 100mg once daily (Qd) is continued for 3 months.
Standard Therapy Group	Active comparator	Drug: Aspirin (Standard, 24h)	Participants receive oral aspirin 100mg once daily (Qd) starting at 24 hours after rt-PA thrombolysis. A follow-up CT scan is performed at 24 hours post-thrombolysis. If no intracranial hemorrhage is confirmed, aspirin 100mg once daily (Qd) is continued for 3 months.

Aspirin (Early, 2h) (Drug): Aspirin 100mg orally, administered once daily. The first dose is given at 2 hours after rt-PA thrombolysis, conditional on a follow-up CT scan at 2 hours excluding intracranial hemorrhage. Treatment continues for 3 months.
Aspirin (Standard, 24h) (Drug): Aspirin 100mg orally, administered once daily. The first dose is given at 24 hours after rt-PA thrombolysis, conditional on a follow-up CT scan at 24 hours confirming no intracranial hemorrhage. Treatment continues for 3 months.

+Outcome measures

Primary outcomes

Proportion of Patients with Favorable Functional Outcome at 3 Months [3 months]: Favorable functional outcome is defined as a score of 0 to 2 on the modified Rankin Scale (mRS). The mRS score will be assessed by a blinded endpoint assessor at 3 months post-stroke via a structured telephone interview or during a clinic visit.

Secondary outcomes

Incidence of symptomatic intracranial hemorrhage [24 hour]
Patient mortality rate at 3 months [3 months]

+Eligibility

Sex: All, ages: 18 Years to 65 Years

Inclusion Criteria:

1. Age range: 18-65 years old
2. Receive rt PA thrombolytic therapy within 3 hours (including 3 hours) of onset
3. Signs of brain dysfunction lasting for more than 1 hour
4. CT imaging excludes cerebral hemorrhage, and there are no imaging changes corresponding to the patient's physical signs

Exclusion Criteria:

1. Age>65 years old
2. Onset time>3 hours
3. Accompanied by consciousness disorders, or NIHSS ≥ 20 points
4. CT shows' high-density shadow of middle cerebral artery '
5. Accompanied by atrial fibrillation or clearly identified as cardioembolic embolism
6. Severe swallowing difficulties, unable to take medication orally
7. Oral anticoagulant medication is currently being taken
8. Accompanied by severe infection or evidence of severe infection
9. Refusal to sign the informed consent form for this study
10. Exclusion criteria for other traditional intravenous thrombolysis

+Locations (1)

Facility	City	Country	Status
Beijng Chao-Yang Hospital, Capital Medical University	Beijing, Beijing Municipality	China